查看購物車
  • English
封面
市場調查報告書
商品編碼
1914540

多重檢測市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、類型、技術、應用、最終用戶、地區和競爭格局分類），2021-2031年

Multiplex Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type, By Technology, By Application (Research & Development, Clinical Diagnosis ), By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球多重檢測市場預計將從2025年的32.1億美元顯著成長至2031年的55.4億美元，複合年成長率（CAGR）達9.52%。多重檢測能夠在單一檢體體積內同時檢測和定量多種分析物，是提高診斷效率的先進分析工具。該市場成長的根本驅動力是慢性病發病率的上升以及藥物研發中對高通量篩檢需求的日益成長。根據美國癌症協會報告，預計2024年美國將新增2,001,140例癌症病例。這項數據凸顯了開發可靠的生物標記分析工具以應對日益成長的疾病負擔的迫切需求。這正推動著多重檢測技術的應用，以簡化工作流程並支持精準醫療舉措。

市場概覽
預測期 2027-2031
市場規模：2025年 32.1億美元
市場規模：2031年 55.4億美元
複合年成長率：2026-2031年 9.52%
成長最快的細分市場 試劑和耗材
最大的市場 北美洲

然而，市場擴張面臨許多障礙，包括自動化設備所需的大量資本投入以及檢測檢驗相關的技術複雜性。開發這些檢測方法需要進行嚴格的最佳化以降低試劑間的交叉反應，而此過程通常耗時耗力。這些挑戰往往會延遲監管核准並增加營運成本，從而限制資源有限的實驗室使用和採用多重檢測技術。

市場促進因素

隨著製藥公司尋求提高研發管線效率，藥物研發投入的不斷成長正從根本上推動全球多重檢測市場的發展。多重檢測技術使研究人員能夠同時篩檢針對多個標靶的化合物，從而加速候選藥物的檢驗和毒性分析。這項投入在產業支出中顯而易見，默克公司2023年年度報告顯示，該公司將在2023年投入305億美元用於研發，這顯示其在治療科學領域投入龐大。如此龐大的預算支持採用能夠最大限度提高數據輸出並降低研發成本的檢測方法。生物製程國際（Bioprocess International）報告稱，賽默飛世爾科技公司於2024年以約31億美元收購了Olink，策略性地將可擴展的蛋白質分析技術納入其產品組合，這進一步印證了該市場的價值。

隨著感染疾病的持續蔓延，對能夠同時檢測多種病原體的診斷工具的需求日益迫切。多重檢測對於區分共存感染疾病至關重要，因為它克服了單重檢測方法固有的樣本量限制。全球衛生統計數據凸顯了這一迫切性。根據世界衛生組織（世衛組織）於2024年10月發布的《2024年全球結核病報告》，預計2023年將新增約820萬例結核病病例，這將是自監測開始以來的最高數字。日益沉重的負擔促使檢查室採用高通量解決方案來高效處理檢體，而醫療機構也擴大轉向多重檢測平台，以簡化工作流程，並在日益嚴峻的流行病學挑戰下確保及時治療。

市場挑戰

阻礙全球多重檢測市場成長的主要挑戰在於自動化設備所需的高額資本投入以及檢測檢驗的技術複雜性。這些重大的財務和營運障礙直接阻礙了市場擴張，使得多重檢測技術的應用僅限於資金雄厚的機構，而資源匱乏的實驗室則幾乎被排除在外。為防止交叉反應並確保檢測可靠性，需要進行嚴格的最佳化，這需要大量的時間和預算，從而增加了總體擁有成本 (TCO)。因此，許多診斷實驗室被迫依賴傳統的低通量方法，阻礙了精準醫療所需的高階多重檢測工作流程的廣泛應用。

這些資源負擔帶來的實際影響體現在近期檢查室運作的產業數據。根據美國實驗室醫學學會 (ADLM) 統計，到 2024 年，48% 的受訪臨床檢查室將停止進行某些檢查室自建檢測項目，原因是滿足日益嚴格的檢驗和監管合規標準需要耗費過多的財力和人力資源。這項數據表明，高昂的營運成本和技術檢驗要求共同迫使檢查室縮減檢測能力，從而限制了多重檢測的整體市場潛力。

市場趨勢

能夠以高解析度繪製組織微環境內細胞異質性的單細胞多重定序平台正快速改變市場模式。與傳統的批量定序（對細胞群體數據進行平均）不同，這些空間生物學技術使研究人員能夠在保留樣本空間背景的同時，可視化多體學圖譜——這對於理解癌症等複雜病理至關重要。這種向空間分析的產業轉型得到了大規模整合活動的支持。例如，布魯克公司在2024年5月的新聞稿中宣布，已完成對NanoString Technologies公司資產的收購，交易金額約為3.926億美元，旨在加強其在空間轉錄組學和基因表現分析領域的實力。

同時，照護現場診斷設備的微型化正在推動分散式檢查的發展，它將複雜的多重分析功能整合到攜帶式微流體平台上。這一趨勢滿足了快速、就近決策的需求，並將診斷模式從集中式高通量檢查室轉向社區醫療機構。主要診斷設備製造商正積極利用這項轉變來擴大分散式檢查的部署。為了支持這一戰略方向，羅氏在2024年1月的新聞稿中宣布，已達成協議以2.95億美元收購LumiraDx的照護現場技術平台，其明確目的是將多種免疫檢測和臨床化學檢測整合到單一設備上，用於分散式醫療保健應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球多重檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按產品分類（試劑和耗材、配件和設備、軟體和服務）
    • 依類型（核酸、蛋白質、細胞來源）
    • 依技術分類（流式細胞技術、螢光檢測、發光法、多重即時即時PCR等）
    • 依應用領域（研發（藥物開發、生物標記發現與檢驗）、臨床診斷（感染疾病、癌症、心血管疾病、自體免疫疾病等））
    • 依最終用戶（製藥/生技公司、醫院/研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美多重檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲多重檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區多重檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲多重檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲多重檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球多重偵測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina, Inc.
  • QIAGEN NV
  • Merck KGaA
  • Abcam plc
  • Becton, Dickinson and Company
  • DiaSorin SpA
  • Seegene Inc.
  • Luminex Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5055

The Global Multiplex Assays Market is projected to expand significantly, growing from USD 3.21 Billion in 2025 to USD 5.54 Billion by 2031, representing a CAGR of 9.52%. Multiplex assays serve as advanced analytical tools that enhance diagnostic efficiency by enabling the simultaneous detection and quantification of multiple analytes within a single sample volume. This market growth is fundamentally underpinned by the increasing prevalence of chronic diseases and the intensified demand for high-throughput screening in drug discovery. As reported by the American Cancer Society, the United States was projected to see 2,001,140 new cancer cases in 2024, a statistic that emphasizes the urgent necessity for robust biomarker profiling tools to manage this escalating disease burden, thereby driving the adoption of multiplexing to streamline workflows and support precision medicine initiatives.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.21 Billion
Market Size 2031USD 5.54 Billion
CAGR 2026-20319.52%
Fastest Growing SegmentReagents & Consumables
Largest MarketNorth America

However, market expansion faces substantial obstacles due to the high capital investment required for automated instrumentation and the technical complexity associated with assay validation. Developing these assays necessitates rigorous optimization to mitigate cross-reactivity between reagents, a process that is often both time-consuming and costly. These challenges frequently delay regulatory approval and increase operational expenses, thereby restricting the accessibility and implementation of multiplex technologies within resource-constrained laboratory settings.

Market Driver

Escalating R&D investments in drug discovery are fundamentally driving the Global Multiplex Assays Market, as pharmaceutical companies aim to improve pipeline efficiency. Multiplexing enables researchers to screen compounds against multiple targets simultaneously, which accelerates candidate validation and toxicity profiling. This commitment is evident in industry spending; according to the Merck & Co. Annual Report 2023, the company allocated $30.5 billion to research and development in 2023, demonstrating a significant investment in therapeutic science. Such budgets support the adoption of assays that maximize data output and reduce development costs. Underscoring this market value, BioProcess International reported in 2024 that Thermo Fisher Scientific acquired Olink for approximately $3.1 billion, strategically adding scalable protein analysis to their portfolio.

The increasing prevalence of infectious diseases further creates a critical need for diagnostic tools capable of simultaneous pathogen detection. Multiplex assays are essential for distinguishing co-occurring infections without the sample limitations inherent in singleplex methods. This urgency is highlighted by global health statistics; the World Health Organization's October 2024 'Global Tuberculosis Report 2024' noted that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, the highest figure since monitoring began. This rising burden compels laboratories to utilize high-throughput solutions for efficient sample processing, leading healthcare providers to transition toward multiplex platforms to streamline workflows and ensure timely treatment amidst growing epidemiological challenges.

Market Challenge

A primary challenge impeding the growth of the Global Multiplex Assays Market is the high capital investment required for automated instrumentation alongside the technical complexity of assay validation. These significant financial and operational barriers directly hamper market expansion by restricting the adoption of multiplexing technologies to well-funded institutions, effectively excluding resource-constrained laboratories. The rigorous optimization needed to prevent cross-reactivity and ensure assay reliability demands substantial time and budget, which increases the total cost of ownership. Consequently, many diagnostic facilities are forced to rely on traditional, lower-throughput methods, thereby stalling the widespread implementation of advanced multiplex workflows necessary for precision medicine.

The tangible impact of these resource burdens is reflected in recent industry data regarding laboratory operations. According to the Association for Diagnostics & Laboratory Medicine, in 2024, 48% of surveyed clinical laboratories indicated they would discontinue performing certain laboratory-developed tests due to the prohibitive financial and personnel resources required to meet stricter validation and regulatory compliance standards. This statistic illustrates how the convergence of high operational costs and technical validation requirements directly forces laboratories to scale back their testing capabilities, limiting the overall addressable market for multiplex assays.

Market Trends

The market is being rapidly transformed by the advancement of single-cell multiplexing platforms, which enable high-resolution mapping of cellular heterogeneity within tissue microenvironments. Unlike traditional bulk sequencing that averages data across cell populations, these spatial biology technologies allow researchers to visualize multi-omic profiles while retaining the spatial context of the sample, a capability crucial for understanding complex pathologies like cancer. This industrial pivot toward spatial analysis is validated by significant consolidation activities; for instance, Bruker Corporation announced in a May 2024 press release that it had finalized the acquisition of NanoString Technologies' assets for approximately $392.6 million to strengthen its portfolio in spatial transcriptomics and gene expression analysis.

Simultaneously, the miniaturization of devices for point-of-care diagnostics is driving decentralized testing by integrating complex multiplex capabilities into portable, microfluidic platforms. This trend addresses the need for rapid, near-patient decision-making, shifting the diagnostic paradigm from centralized, high-volume laboratories to community-based settings. Major diagnostic leaders are actively capitalizing on this shift to expand their decentralized testing footprints. Validating this strategic direction, Roche announced in a January 2024 press release its agreement to acquire LumiraDx's point-of-care technology platform for a purchase price of $295 million, explicitly to integrate multiple immunoassay and clinical chemistry tests onto a single instrument for decentralized healthcare use.

Key Market Players

  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina, Inc.
  • QIAGEN N.V.
  • Merck KGaA
  • Abcam plc
  • Becton, Dickinson and Company
  • DiaSorin S.p.A.
  • Seegene Inc.
  • Luminex Corporation

Report Scope

In this report, the Global Multiplex Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiplex Assays Market, By Product

  • Reagents & Consumables
  • Accessories & Instruments
  • Software & Services

Multiplex Assays Market, By Type

  • Nucleic Acid
  • Protein
  • Cell-based

Multiplex Assays Market, By Technology

  • Flow Cytometry
  • Fluorescence Detection
  • Luminescence
  • Multiplex Real-Time PCR
  • Others

Multiplex Assays Market, By Application

  • Research & Development (Drug Development)
  • Biomarker Discovery & Validation
  • Clinical Diagnosis (Infectious Disease)
  • Cancer
  • Cardiovascular Disease
  • Autoimmune Disease
  • Others

Multiplex Assays Market, By End User

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Research Institutes
  • Others

Multiplex Assays Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multiplex Assays Market.

Available Customizations:

Global Multiplex Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multiplex Assays Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Reagents & Consumables, Accessories & Instruments, Software & Services)
    • 5.2.2. By Type (Nucleic Acid, Protein, Cell-based)
    • 5.2.3. By Technology (Flow Cytometry, Fluorescence Detection, Luminescence, Multiplex Real-Time PCR, Others)
    • 5.2.4. By Application (Research & Development (Drug Development, Biomarker Discovery & Validation), Clinical Diagnosis (Infectious Disease, Cancer, Cardiovascular Disease, Autoimmune Disease, Others))
    • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Multiplex Assays Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Multiplex Assays Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Multiplex Assays Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Multiplex Assays Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Multiplex Assays Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Multiplex Assays Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Multiplex Assays Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Multiplex Assays Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Multiplex Assays Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Multiplex Assays Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia Pacific Multiplex Assays Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Multiplex Assays Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Multiplex Assays Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Multiplex Assays Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Multiplex Assays Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Multiplex Assays Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Middle East & Africa Multiplex Assays Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Multiplex Assays Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Multiplex Assays Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Multiplex Assays Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. South America Multiplex Assays Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Multiplex Assays Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Multiplex Assays Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Multiplex Assays Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Multiplex Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Rad Laboratories
  • 15.3. Illumina, Inc.
  • 15.4. QIAGEN N.V.
  • 15.5. Merck KGaA
  • 15.6. Abcam plc
  • 15.7. Becton, Dickinson and Company
  • 15.8. DiaSorin S.p.A.
  • 15.9. Seegene Inc.
  • 15.10. Luminex Corporation

16. Strategic Recommendations

17. About Us & Disclaimer